Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Completed
Pfizer
Phase 2
2004-11-01
Determine if there is a difference in treatment response for adults with ADHD who are treated
with Strattera versus those treated with a combination of Strattera and buspirone
Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
Completed
Eli Lilly and Company
Phase 4
2003-12-01
This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the
treatment of adults with attention deficit hyperactivity disorder not otherwise specified.
The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to
Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day,
whichever is less) in adults with ADHD NOS will be safe and well tolerated.
Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
Completed
Massachusetts General Hospital
Phase 4
2003-12-01
This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the
treatment of adults with attention deficit hyperactivity disorder not otherwise specified.
The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to
Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day,
whichever is less) in adults with ADHD NOS will be safe and well tolerated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
